1. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype
- Author
-
Reoto Takei, Kevin K. Brown, Yasuhiko Yamano, Kensuke Kataoka, Toshiki Yokoyama, Toshiaki Matsuda, Tomoki Kimura, Atsushi Suzuki, Taiki Furukawa, Junya Fukuoka, Takeshi Johkoh, Yoshihito Goto, and Yasuhiro Kondoh
- Subjects
Pulmonary and Respiratory Medicine ,Phenotype ,Vital Capacity ,Disease Progression ,Prevalence ,Humans ,Lung Diseases, Interstitial ,Prognosis ,Fibrosis ,Idiopathic Pulmonary Fibrosis - Abstract
The development of clinically progressive fibrosis complicates a wide array of interstitial lung diseases (ILDs). However, there are limited data regarding its prevalence and prognosis.We analysed consecutive patients seen for initial evaluation of a fibrosing form of ILD (FILD). Patients were evaluated for evidence of progressive fibrosis over the first 24 months of follow-up. We defined a progressive phenotype as the presence of at least one of the following: a relative decline in forced vital capacity (FVC) of ≥10%; a relative decline in FVC of ≥5%-10% with a relative decline in diffusing capacity of the lung for carbon monoxide of ≥15%, increased fibrosis on HRCT or progressive symptoms.Eight hundred and forty-four patients (397 with idiopathic pulmonary fibrosis [IPF] and 447 non-IPF FILD) made up the final analysis cohort. Three hundred and fifty-five patients (42.1%) met the progressive phenotype criteria (59.4% of IPF patients and 26.6% of non-IPF FILD patients, p 0.01). In both IPF and non-IPF FILD, transplantation-free survival differed between patients with a progressive phenotype and those without (p 0.01). Multivariable analysis showed that a progressive phenotype was an independent predictor of transplantation-free survival (hazard ratio [HR]: 3.36, 95% CI: 2.68-4.23, p 0.01). Transplantation-free survival did not differ between non-IPF FILD with a progressive phenotype and IPF (HR: 1.12, 95% CI: 0.85-1.48, p = 0.42).Over one-fourth of non-IPF FILD patients develop a progressive phenotype compared to approximately 60% of IPF patients. The survival of non-IPF FILD patients with a progressive phenotype is similar to IPF.
- Published
- 2022
- Full Text
- View/download PDF